<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRP</journal-id><journal-title-group><journal-title>Asian Case Reports in Pediatrics</journal-title></journal-title-group><issn pub-type="epub">2328-045X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRP.2020.82004</article-id><article-id pub-id-type="publisher-id">ACRP-35600</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRP20200200000_17450436.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  英夫利昔单抗治疗IVIG无反应型川崎病的进展
  Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>木雯</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>余</surname><given-names>更生</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆医科大学附属儿童医院，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>21</day><month>04</month><year>2020</year></pub-date><volume>08</volume><issue>02</issue><fpage>18</fpage><lpage>22</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病，病因尚不清楚，静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应，但仍有部分患者对治疗无反应，本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。
    Kawasaki disease is an acute self-limited disease characterized by systemic vasculitis; etiology is unclear; intravenous immunoglobulin and aspirin therapy can alleviate the inflammation of Kawasaki disease, but there are still some patients do not respond to treatment. This review focuses on the application of infliximab in IVIG reactive Kawasaki disease. 
  
 
</p></abstract><kwd-group><kwd>IVIG无反应型川崎病，英夫利昔单抗，综述, IVIG-Resistant Kawasaki Disease</kwd><kwd> Infliximab</kwd><kwd> Reviews</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>英夫利昔单抗治疗IVIG无反应型川崎病的进展<sup> </sup></title><p>宋木雯，余更生</p><p>重庆医科大学附属儿童医院，重庆</p><p>收稿日期：2020年4月18日；录用日期：2020年5月11日；发布日期：2020年5月18日</p><disp-formula id="hanspub.35600-formula39"><graphic xlink:href="//html.hanspub.org/file/2-2460107x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>川崎病(Kawasaki disease, KD)是一种以全身性血管炎为特征的急性自限性疾病，病因尚不清楚，静脉注射丙种球蛋白(intravenous immunoglobulin, IVIG)联合阿司匹林治疗可缓解川崎病的炎症反应，但仍有部分患者对治疗无反应，本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。</p><p>关键词 :IVIG无反应型川崎病，英夫利昔单抗，综述</p><disp-formula id="hanspub.35600-formula40"><graphic xlink:href="//html.hanspub.org/file/2-2460107x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2460107x7_hanspub.png" /> <img src="//html.hanspub.org/file/2-2460107x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>川崎病(Kawasaki disease, KD)是一种急性、自限性疾病，其特征性表现为血管的急性炎症，主要累及皮肤、眼睛、淋巴结和粘膜层。虽然这种疾病通常是自限性的，患者在发病后几周可自愈，但有15%~25%的患者在未接受适当治疗的情况下出现冠状动脉损害(Coronary artery lesions, CALs) [<xref ref-type="bibr" rid="hanspub.35600-ref1">1</xref>]。阿司匹林联合静脉注射丙种球蛋白(Intravenous immunoglobulin, IVIG)治疗对于川崎病的炎症有明显缓解作用，可降低CALs的风险，但仍有部分患者对治疗无反应，会增加CALs的发生风险。对于IVIG无反应的川崎病患者的继续治疗目前成为了关注的焦点。肿瘤坏死因子-α (Tumor necrosis factor-α, TNF-α)在KD急性期升高，在随后发展为冠状动脉瘤的儿童中水平最高 [<xref ref-type="bibr" rid="hanspub.35600-ref2">2</xref>]，而TNF抑制剂能降低炎症和动脉内膜炎。因此，TNF抑制剂可能在IVIG无反应型KD的治疗中具有心脏保护作用。本文主要针对英夫利昔单抗在IVIG无反应型川崎病中的应用进行综述。</p></sec><sec id="s4"><title>2. 川崎病概述</title><p>川崎病(Kawasaki disease, KD)是一种自身免疫性疾病，早期表现为一种急性的、自限性的、高度炎症的状态，它主要影响全身中小动脉，特别是冠状动脉。诊断主要依靠临床表现，包括持续发热≥5天，伴有皮疹、颈部非脓性淋巴结肿大、眼结合膜充血、口腔黏膜弥漫充血、杨梅舌、掌跖红斑、手足硬性水肿等。川崎病常见于5岁以下儿童 [<xref ref-type="bibr" rid="hanspub.35600-ref3">3</xref>]，男孩患此病的风险是女孩的1.5倍 [<xref ref-type="bibr" rid="hanspub.35600-ref4">4</xref>]，流行病学模式在不同的地理位置上差别很大，发病率因种族和季节而异。虽然在大多数情况下，KD是一种自限性疾病，在发热后几周内即可痊愈，但仍有15%~25%的患者在未接受适当治疗的情况下在2~4周内常出现冠状动脉损伤(coronary artery lesions, CAL)。大剂量的丙种球蛋白联合阿司匹林治疗通常可在1~2天内退热，并可将CAL发生率降低到3%左右 [<xref ref-type="bibr" rid="hanspub.35600-ref1">1</xref>]。然而，总共有10%~20%的KD患者在接受初始丙种球蛋白治疗超过36小时出现反复或持续发热，被定义为IVIG无反应型川崎病或难治性川崎病，这些患者有较高的CAL患病率，从10.0%到33.3%不等 [<xref ref-type="bibr" rid="hanspub.35600-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.35600-ref6">6</xref>]。目前类固醇、英夫利昔单抗(IFX)、环孢素和血浆置换等已被证明对难治性川崎病患者的急性期治疗有效。但这些治疗的有效性仍存在较大的争议，一项回顾性研究 [<xref ref-type="bibr" rid="hanspub.35600-ref7">7</xref>] 显示，IVIG无反应KD患者在发生CALs后进行血浆置换可显著降低血清C反应蛋白水平，并且可显著改善冠状动脉损伤。另外有研究 [<xref ref-type="bibr" rid="hanspub.35600-ref8">8</xref>] 显示环孢素可能能够降低川崎病血浆炎性细胞因子水平，但其对于缓解冠状动脉病变是否有效证据尚不足。因此，选择一个最佳的安全有效的治疗方案是目前迫切需要的。</p></sec><sec id="s5"><title>3. 川崎病的发病机制</title><p>关于KD的病因，人们提出了许多假说，从病毒病因到毒素介导的自身炎症反应。然而目前KD的确切病因尚不清楚，但人们普遍认为是在遗传易感个体中由感染触发随后激活异常免疫应答有关 [<xref ref-type="bibr" rid="hanspub.35600-ref9">9</xref>]。KD的免疫激活与内皮细胞损伤有关，而内皮细胞的损伤这可能是由于细胞因子的异常产生和抗内皮细胞的细胞毒性抗体的产生所致。有研究显示在KD急性期，血清中TNF-α、白细胞介素-10、白细胞介素-6水平在IVIG治疗前显著升高，在IVIG治疗后，未发生CALs的KD患者TNF-α水平明显降低，而发生CALs的以及IVIG抵抗的KD患者TNF-α水平升高 [<xref ref-type="bibr" rid="hanspub.35600-ref10">10</xref>]。TNF-α最初由T淋巴细胞产生随后由单核或巨噬细胞释放，是调节内皮细胞活化和损伤的主要炎性细胞因子之一，在KD的发病中发挥着重要作用。它通过增加粘附分子的表达和促进白细胞–内皮细胞相互作用所需的趋化因子的释放来激活内皮细胞 [<xref ref-type="bibr" rid="hanspub.35600-ref11">11</xref>]。基质金属蛋白酶(matrix metalloproteinase, MMP)是一种降解酶，通过破坏细胞外基质蛋白(如弹性蛋白)，在血管重建中发挥重要作用。TNF-α也通过激活MMP-9从而导致弹力蛋白断裂与血管壁动脉瘤形成 [<xref ref-type="bibr" rid="hanspub.35600-ref12">12</xref>]。在KD的动物模型中也表明，TNF-α参与了冠状动脉瘤的发展 [<xref ref-type="bibr" rid="hanspub.35600-ref13">13</xref>]。鉴于此，通过阻滞TNF-α来治疗KD成为目前治疗新选择。</p></sec><sec id="s6"><title>4. 英夫利昔单抗在IVIG无反应型川崎病中的应用</title><p>英夫利昔单抗(Infliximab, IFX)是一种单克隆抗体，是目前常用的肿瘤坏死因子阻滞剂，在许多研究中被报道可用于治疗难治性KD。2004年，Weiss等人 [<xref ref-type="bibr" rid="hanspub.35600-ref14">14</xref>] 首次报道IFX给药于一名3岁的IVIG无反应型KD患者。随后，Burns等人 [<xref ref-type="bibr" rid="hanspub.35600-ref15">15</xref>] 在2005年的一项研究显示IVIG无反应型KD患者给予英夫利昔单抗治疗后可明显改善症状，且无英夫利昔单抗相关不良事件发生。Son等人 [<xref ref-type="bibr" rid="hanspub.35600-ref16">16</xref>] 在2000年1月至2008年3月的一项关于初始IVIG治疗无效的KD患儿的继续治疗的回顾性研究中，比较了改用IFX治疗和继续使用IVIG治疗两者间的疗效，研究结果显示两组冠状动脉病变的发生并没有显著差异。但英夫利昔单抗组发热天数更少(中位数8天vs 10天，P = 0.028)，在多变量分析中，英夫利昔单抗组发热天数少于1.2天(P = 0.033)。接受英夫利昔单抗治疗的患者住院时间较短(中位数5.5天vs 6天，P = 0.040)。治疗组在不良事件方面没有显著差异(0%比2.3%，P = 1.0)。Youn等人 [<xref ref-type="bibr" rid="hanspub.35600-ref17">17</xref>]、张鹏宇 [<xref ref-type="bibr" rid="hanspub.35600-ref18">18</xref>] 等人研究也提示，在IVIG无反应型川崎病患者的治疗中，英夫利昔单抗治疗应答率更高，并且能缩短患儿发热时间，且安全性良好，但不能改善冠状动脉损害。</p><p>然而，一项涉及KD的研究 [<xref ref-type="bibr" rid="hanspub.35600-ref19">19</xref>]，将IVIG联合IFX作为KD患者的初始治疗，结果表示，IVIG联合IFX治疗可以缩短KD患者的发热时间，降低炎症标志物，并降低左冠状动脉前降支z值。Nagatomo等人 [<xref ref-type="bibr" rid="hanspub.35600-ref20">20</xref>] 在2018的一项研究中评估IFX是否与冠状动脉瘤(CAA)消退相关，选取49例有CAA的KD患者分为两组：27例接受IFX治疗，22例未接受。接受IFX治疗组CRP的最大值高于未接受IFX治疗组，最大z值(z-max)在各组间无差异。IFX组2年、4年和6年的CAA累积持续率分别为24%、24%和24%，而非IFX组分别为67%、52%和33% (P = 0.03)。两组CAA消退的中位时间分别是1.1年、4.6年。在中–大型CAAs患者中，IFX组2年、4年和6年的CAA累积持续率分别为33%、33%和33%，而非IFX组分别为77%、51%和48% (P = 0.047)。多因素logistic回归分析显示，CAAs的z-max (HR 0.72, P &lt; 0.001)和对IFX有反应(HR 4.56, P = 0.017)与CAA消退独立相关。提示IFX治疗与难治性KD患者CAAs的早期消退有关。早期退化在对IFX治疗有反应的患者中更明显。IFX不仅可以抑制导致CAAs发展的炎症反应，还可以协助/完成早期CAA退化后的血管重建。日本的Yusaku等 [<xref ref-type="bibr" rid="hanspub.35600-ref21">21</xref>] 的一项研究中结果与之相似，提示IFX可能对于IVIG无反应型川崎患儿的冠状动脉远期预后有更好的效果。</p><p>Hur等 [<xref ref-type="bibr" rid="hanspub.35600-ref22">22</xref>] 研究中将102名首次IVIG治疗无效后的KD患儿根据英夫利昔单抗的给药时间分为两组。早期治疗组(组1)英夫利昔单抗输注前的发热时间(10.5 &#177; 4.4天)较晚期治疗组(组2)短(16.4 &#177; 4.5天)；P &lt; 0.001)。结果显示CAA发生率组1低于组2 (1/42 [2.4%] vs. 17/60 [28.3%], P &lt; 0.001)。提示早期应用英夫利昔单抗可降低IVIG抵抗KD患者CAA的发生率。</p><p>Shimada等 [<xref ref-type="bibr" rid="hanspub.35600-ref23">23</xref>] 研究了16例最终接受了血浆置换的IVIG无反应型KD患者，研究结果显示，血浆置换前接受IFX治疗组比未接受IFX治疗组所需要的总血浆交换次数更少(P = 0.002)，第一次血浆交换前后C反应蛋白的变化和降低率更高(均P = 0.027)。并且由于增加了IFX的PE治疗次数的减少，并没有增加冠状动脉病变的发生。</p></sec><sec id="s7"><title>5. 英夫利昔单抗的安全性</title><p>IFX是嵌合抗体，最常见的不良反应为过敏反应 [<xref ref-type="bibr" rid="hanspub.35600-ref24">24</xref>]。最常见的输液反应是脸红和气促 [<xref ref-type="bibr" rid="hanspub.35600-ref25">25</xref>]。Son等人 [<xref ref-type="bibr" rid="hanspub.35600-ref16">16</xref>] 的研究中在门诊随访的7例患者中发现了短暂性肝肿大，但由于该研究为回顾性分析，未收集患者的ALT水平，所以患者的肝肿大的发展是否与潜在的疾病、治疗或多种因素相关尚不清楚。据报道，KD患者存在肝肿大，其病因可能是心功能障碍，更常见的是急性肝脏炎症和胆囊积液 [<xref ref-type="bibr" rid="hanspub.35600-ref26">26</xref>]。在接受英夫利昔单抗治疗的自身免疫性疾病患者中，也有肝并发症的报道 [<xref ref-type="bibr" rid="hanspub.35600-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.35600-ref28">28</xref>]。但在Mori等人 [<xref ref-type="bibr" rid="hanspub.35600-ref29">29</xref>] 的研究中不良反均为输液反应(IVIG组5例，IFX组1例)，两组均未发现肝损伤。另外，有研究表示，英夫利昔单抗可能导致潜伏性肺结核的复发风险的增加 [<xref ref-type="bibr" rid="hanspub.35600-ref30">30</xref>]。由于英夫利昔单抗在大多数难治性KD患者中仅使用一次，因此，与反复使用的克罗恩病或幼年特发性关节炎患者相比，使用英夫利昔单抗在KD患者中引起的并发症较少。</p><p>综上所述，英夫利昔单抗应用于治疗IVIG无反应型川崎病是安全且有效的，但是对于英夫利昔单抗能否减少冠状动脉异常的发生尚存在较大争议，这尚需更多大样本、多中心、随机、双盲的前瞻性临床对照研究来评估。且国内对此报导也较少，这也是国内今后研究的一个重点。</p></sec><sec id="s8"><title>文章引用</title><p>宋木雯,余更生. 英夫利昔单抗治疗IVIG无反应型川崎病的进展Progress in the Treatment of IVIG-Resistant Kawasaki Disease with Infliximab[J]. 亚洲儿科病例研究, 2020, 08(02): 18-22. https://doi.org/10.12677/ACRP.2020.82004</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35600-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Yeun, K.K. and Soo, K.D. (2016) Recent Advances in Kawasaki Disease. Yonsei Medical Journal, 57, 15.  
https://doi.org/10.3349/ymj.2016.57.1.15</mixed-citation></ref><ref id="hanspub.35600-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Campbell, A.J. and Burns, J.C. (2016) Adjunctive Therapies for Kawasaki Disease. Journal of Infection, 72, S1-S5.  
https://doi.org/10.1016/j.jinf.2016.04.015</mixed-citation></ref><ref id="hanspub.35600-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Saneeymehri, S., Baker, K. and So, T.Y. (2015) Overview of Pharmacological Treatment Options for Pediatric Patients with Refractory Kawasaki Disease. Journal of Pediatric Pharmacology &amp; Therapeutics, 20, 163-177.</mixed-citation></ref><ref id="hanspub.35600-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088.</mixed-citation></ref><ref id="hanspub.35600-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Wallace, C.A., French, J.W., Kahn, S.J., et al. (2000) Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki Disease. Pediatrics, 105, e78. https://doi.org/10.1542/peds.105.6.e78</mixed-citation></ref><ref id="hanspub.35600-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kim, T.Y., Choi, W.S., Woo, C.W., et al. (2007) Predictive Risk Factors for Coronary Artery Abnormalities in Kawasaki Disease. European Journal of Pediatrics, 166, 421-425. https://doi.org/10.1007/s00431-006-0251-8</mixed-citation></ref><ref id="hanspub.35600-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kaida, Y., Kambe, T., Kishimoto, S., Koteda, Y., Suda, K., Yamamoto, R., Imai, T., Hazama, T., Takamiya, Y., Shibata, R., Nishida, H., Okuda, S. and Fukami, K. (2017) Efficacy and Safety of Plasma Exchange for Kawasaki Disease with Coronary Artery Dilatation. Renal Replacement Therapy, 3, Article No. 50.  
https://doi.org/10.1186/s41100-017-0130-y</mixed-citation></ref><ref id="hanspub.35600-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hamada, H., Suzuki, H., Abe, J., et al. (2012) Inflammatory Cytokineprofiles during Cyclosporin Treatment for Immunoglobulin-Resistant Kawasaki Disease. Cytokine, 60, 681-685. https://doi.org/10.1016/j.cyto.2012.08.006</mixed-citation></ref><ref id="hanspub.35600-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) The Present and Future: Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749. https://doi.org/10.1016/j.jacc.2015.12.073</mixed-citation></ref><ref id="hanspub.35600-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Wang, W., Gong, F., et al. (2013) Evaluation of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions in Relation to Th1/Th2 Cytokine Profiles in Patients with Kawasaki Disease. Arthritis &amp; Rheumatology, 65, 805-814. https://doi.org/10.1002/art.37815</mixed-citation></ref><ref id="hanspub.35600-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Takahashi, K., Oharaseki, T. and Yokouchi, Y. (2014) Update on Etio and Immunopathogenesis of Kawasaki Disease. Current Opinion in Rheumatology, 26, 31-36. https://doi.org/10.1097/BOR.0000000000000010</mixed-citation></ref><ref id="hanspub.35600-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Agarwal, S. and Agrawal, D.K. (2016) Kawasaki Disease: Etiopathogenesis and Novel Treatment Strategies. Expert Review of Clinical Immunology, 13, 247. https://doi.org/10.1080/1744666X.2017.1232165</mixed-citation></ref><ref id="hanspub.35600-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Hui-Yuen, J.S., Duong, T.T. and Yeung, R.S. (2006) TNF-Alpha Is Necessary for Induction of Coronary Artery Inflammation and Aneurysm Formation in an Animal Model of Kawasaki Disease. The Journal of Immunology, 176, 6294-6301. https://doi.org/10.4049/jimmunol.176.10.6294</mixed-citation></ref><ref id="hanspub.35600-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Weiss, J.E., Eberhard, B.A., Chowdhury, D., et al. (2004) Infliximab as a Novel Therapy for Refractory Kawasaki Disease. Journal of Rheumatology, 31, 808-810.</mixed-citation></ref><ref id="hanspub.35600-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Burns, J.C., Mason, W.H., Hauger, S.B., et al. (2005) Infliximab Treatment for Refractory Kawasaki Syndrome. Journal of Pediatrics, 146, 662-667. https://doi.org/10.1016/j.jpeds.2004.12.022</mixed-citation></ref><ref id="hanspub.35600-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Son, M.B., Gauvreau, K., Burns, J.C., et al. (2011) Infliximab for Intravenous Immunoglobulin Resistance in Kawasaki Disease: A Retrospective Study. Journal of Pediatrics, 158, 644-649.e1. https://doi.org/10.1016/j.jpeds.2010.10.012</mixed-citation></ref><ref id="hanspub.35600-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Youn, Y., Kim, J., Hong, Y.M., et al. (2015) Infliximab as the First Retreatment in Patients with Kawasaki Disease Resistant to Initial Intravenous Immunoglobulin. Pediatric Infectious Disease Journal, 35, 457.  
https://doi.org/10.1097/INF.0000000000001039</mixed-citation></ref><ref id="hanspub.35600-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">张鹏宇, 汤楚中, 潘绪, 等. 英夫利西单抗与IVIG治疗IVIG初治无效川崎病效果比较[J]. 中国医学前沿杂志(电子版), 2018, 10(5): 66-69.</mixed-citation></ref><ref id="hanspub.35600-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Tremoulet, A.H., Jain, S., Jaggi, P., Jimenez-Fernandez, S., Pancheri, J.M., Sun, X., et al. (2014) Infliximab for Intensification of Primary Therapy for Kawasaki Disease: A Phase 3 Randomised, Double-Blind, Placebo-Controlled Trial. The Lancet, 383, 1731-1738. https://doi.org/10.1016/S0140-6736(13)62298-9</mixed-citation></ref><ref id="hanspub.35600-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Nagatomo, K., Muneuchi, J., Nakashima, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.  
https://doi.org/10.1016/j.ijcard.2018.04.062</mixed-citation></ref><ref id="hanspub.35600-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Nagatomo, Y., et al. (2018) Effective Infliximab Therapy for the Early Regression of Coronary Artery Aneurysm in Kawasaki Disease. International Journal of Cardiology, 271, 317-321.</mixed-citation></ref><ref id="hanspub.35600-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hur, G., Song, M.S., Sohn, S., Lee, H.D., Kim, G.B., Cho, H.J., et al. (2019) Infliximab Treatment for Intravenous Immunoglobulin-Resistant Kawasaki Disease: A Multicenter Study in Korea. Korean Circulation Journal, 49, 183-191.  
https://doi.org/10.4070/kcj.2018.0214</mixed-citation></ref><ref id="hanspub.35600-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shimada, S., Matsuoka, D., Murase, T., et al. (2020) Impact of Infliximab Administration before Plasma Exchange Therapy on Patients with Kawasaki Disease. Therapeutic Apheresis and Dialysis.  
https://doi.org/10.1111/1744-9987.13486</mixed-citation></ref><ref id="hanspub.35600-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sonoda, K., Mori, M., Hokosaki, T., et al. (2014) Infliximab plus Plasma Exchange Rescue Therapy in Kawasaki Disease. The Journal of Pediatrics, 164, 1128-1132. https://doi.org/10.1016/j.jpeds.2014.01.020</mixed-citation></ref><ref id="hanspub.35600-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Crandall, W.V. and Mackner, L.M. (2003) Infusion Reactions to Infliximab in Children and Adolescents: Frequency, Outcome and a Predictive Model. Alimentary Pharmacology &amp; Therapeutics, 17, 75-84.  
https://doi.org/10.1046/j.1365-2036.2003.01411.x</mixed-citation></ref><ref id="hanspub.35600-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Chen, W.T., Huang, S.R. and Wang, J.K. (2003) Kawasaki Disease Presenting with Hepatitis and Prolonged Fever: Report of One Case. Acta Paediatrica Taiwanica, 44, 174-176.</mixed-citation></ref><ref id="hanspub.35600-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ierardi, E., Valle, N.D., Nacchiero, M.C., et al. (2006) Onset of Liver Damage after a Single Administration of Infliximab in a Patient with Refractory Ulcerative Colitis. Clinical Drug Investigation, 26, 673-676.  
https://doi.org/10.2165/00044011-200626110-00008</mixed-citation></ref><ref id="hanspub.35600-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ozorio, G., McGarity, B., Bak, H., Jordan, A.S., Lau, H. and Marshall, C. (2007) Autoimmune Hepatitis Following Infliximab Therapy for Ankylosing Spondylitis. The Medical Journal of Australia, 187, 524-526.  
https://doi.org/10.5694/j.1326-5377.2007.tb01396.x</mixed-citation></ref><ref id="hanspub.35600-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mori, M., Hara, T., Kikuchi, M., et al. (2018) Infliximab versus Intravenous Immunoglobulin for Refractory Kawasaki Disease: A Phase 3, Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Trial. Scientific Reports, 8, Article No. 1994. https://doi.org/10.1038/s41598-017-18387-7</mixed-citation></ref><ref id="hanspub.35600-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Keane, J., Gershon, S., Wise, R.P., et al. (2001) Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor Alpha-Neutralizing Agent. The New England Journal of Medicine, 345, 1098-1104.  
https://doi.org/10.1056/NEJMoa011110</mixed-citation></ref></ref-list></back></article>